Welcome to our dedicated page for DELCATH SYSTEMS SEC filings (Ticker: DCTH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on DELCATH SYSTEMS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into DELCATH SYSTEMS's regulatory disclosures and financial reporting.
DELCATH SYSTEMS, INC. director John Richard Sylvester received a grant of stock options for 22,500 shares of common stock at an exercise price of $11.61 per share. The options vest in equal monthly installments, with one-twelfth vesting each month starting on May 13, 2026, as long as he remains a director. Any vested options expire the earlier of 10 years from the grant date or two years after his last day of service.
DELCATH SYSTEMS, INC. director Bridget A. Martell received a grant of stock options as equity compensation. The award covers 22,500 options for common stock at an exercise price of $11.61 per share, and she now holds 22,500 options following this grant.
These options vest in equal monthly installments of one-twelfth, starting on May 13, 2026, as long as she continues serving as a director under the company’s 2020 Omnibus Equity Incentive Plan. The options expire on the earlier of 10 years from grant or two years after her service ends for vested portions.
DELCATH SYSTEMS, INC. director Elizabeth Czerepak received a grant of stock options covering 22,500 shares of common stock. The options have an exercise price of $11.61 per share and are compensation rather than an open-market purchase.
The award vests at a rate of one-twelfth per month, with the first vesting on May 13, 2026 and monthly thereafter while she remains a director under the company’s 2020 Omnibus Equity Incentive Plan. Any unexercised options will expire the earlier of 10 years from the grant date or two years after her service ends.
DELCATH SYSTEMS, INC. director Steven A. J. Salamon received a grant of stock options covering 22,500 shares of common stock. The options have an exercise price of $11.61 per share and represent a compensation-related award, not an open-market purchase.
The options vest in equal monthly installments of one-twelfth of the grant, starting on May 13, 2026, as long as he continues serving as a director under the company’s 2020 Omnibus Equity Incentive Plan. The options expire 10 years from the grant date or, for vested portions, two years after his last day of service.
DELCATH SYSTEMS, INC. director Aharon Gil received a grant of stock options covering 22,500 shares of common stock. The options have an exercise price of $11.61 per share and were awarded as compensation, not through an open-market purchase or sale.
The grant vests in equal monthly installments of one-twelfth of the total, starting on May 13, 2026, so long as Gil remains a director and subject to the company’s 2020 Omnibus Equity Incentive Plan. Any unexercised options will expire the earlier of 10 years from grant or two years after service ends.
Delcath Systems, Inc. reported the results of its 2026 annual meeting of stockholders, where investors approved increasing the 2020 Omnibus Equity Incentive Plan by 1,800,000 shares of common stock. The plan provides additional shares for future equity-based awards to employees, directors and other participants.
Stockholders also elected two Class II directors to serve until the 2029 annual meeting, ratified CBIZ CPAs P.C. as independent auditor for the year ending December 31, 2026, and approved a non-binding advisory vote on executive compensation. Of 34,618,159 eligible common and convertible preferred shares, 23,346,271 shares, or about 67.44%, were represented at the meeting, indicating a solid voting turnout.
Delcath Systems, Inc. reported first-quarter 2026 revenue of $24.99 million, up from $19.78 million a year earlier, driven by continued uptake of the HEPZATO KIT in the United States. CHEMOSAT contributed $1.75 million, roughly flat year over year.
Gross profit rose to $21.26 million, but higher research and development spending of $9.82 million and selling, general and administrative expenses of $13.07 million led to a net loss of $1.07 million, compared with net income of $1.07 million in the prior-year quarter.
The company ended March 31, 2026 with $41.3 million in cash and cash equivalents and $48.0 million in short-term investments, and believes this liquidity will fund operations for at least 12 months. Delcath is advancing Phase 2 trials of HEPZATO in liver-dominant metastatic colorectal and breast cancer and continues a share repurchase program, having bought back approximately $9.0 million of stock under a $25.0 million authorization.
Delcath Systems reported first quarter 2026 revenue of $25.0 million, up from $19.8 million a year earlier, driven by $23.3 million from HEPZATO KIT and $1.7 million from CHEMOSAT. Gross margin was 85%.
The company posted a net loss of $1.1 million versus net income of $1.1 million in the prior-year quarter, and non-GAAP adjusted EBITDA declined to $3.4 million from $7.6 million. Delcath ended March 31, 2026 with $89.3 million in cash and investments and no debt, and repurchased 316,023 shares for about $3.0 million.
For full-year 2026, Delcath expects total HEPZATO KIT and CHEMOSAT revenue of at least $100 million, gross margins between 84% and 87%, and positive adjusted EBITDA. The quarter also featured publication of Phase 2 CHOPIN trial results and new clinical guideline recognition for CHEMOSAT.
BlackRock, Inc. reports 1,733,824 shares of DELCATH SYS INC common stock, representing 4.98% of the class as of 03/31/2026. The filing shows sole voting power for 1,703,693 shares and sole dispositive power for 1,733,824 shares. The filing is a Schedule 13G/A amendment reporting ownership by BlackRock Reporting Business Units.